Pre-emptive administration of fibrinogen concentrate effective in severe trauma: BMJ

The Results of the study are as follows:

∼56% of patients with an ISS ≥26 and transfused with red blood cell concentrates ≥10 units, had hypofibrinogenemia (fibrinogen <1.5 g/L) on arrival. Patients who received fibrinogen concentrate in group C showed significantly higher fibrinogen levels after treatment with this agent than those in group B (2.41 g/L vs 1.88 g/L; p=0.01). Although no significant difference was observed in blood transfusion volumes between the groups, the 30-day survival of patients in group C (all, and those with an ISS ≥26) was significantly better than in group A (p<0.05). The 48-hour mortality rate in patients with an ISS ≥26 was significantly lower in group C than in group A (8.6% vs 22.9%; p=0.005). Further, among patients with an ISS ≥41, the overall mortality was significantly lower in group C than in group A (20% vs 50%; p=0.02).

Thus, the researchers concluded that pre-emptive administration of fibrinogen concentrate for patients with trauma with critical coagulopathy may contribute to improved survival.

Reference:

Pre-emptive administration of fibrinogen concentrate contributes to improved prognosis in patients with severe trauma by Koji Yamamoto et al. published in the BMJ Journals: Trauma Surgery & Acute Care.

https://tsaco.bmj.com/content/1/1/e000037